The plight of ADHD and Depression patients seeking medical cannabis in Germany, with Maximillian Plenert

The plight of ADHD and Depression patients seeking medical cannabis in Germany, with Maximillian Plenert

The plight of ADHD and Depression patients seeking medical cannabis in Germany, with Maximillian Plenert. We spoke with the speaker of the German cannabis patients’ association Maximillian Plenert. He explained that recent law changes have allowed for health insurance coverage of cannabis medicines, but that companies don’t want to cover them for conditions like ADHD or depression. He says 1 gram of cannabis from a pharmacy costs more than 20 Euro (22 USD, 32 AUD), so without insurance coverage, many patients turn back to the black market.

The plight of ADHD and Depression patients

Adding to the challenges faces by patients, many doctors don’t want to prescribe cannabis for these conditions. Maximilian also runs a patient hotline that is constantly taking calls from frustrated ADHD patients who can’t get access to or afford the cannabis medicines that help them to function well. He says ADHD patients are the largest homogenous group of patients and suggest the possibility of bringing many of together to “crash into the system” and raise awareness of their terrible struggles to access and/or afford cannabis medicines.

IACM Conference on Cannabinoids in Medicine aims to advance knowledge on cannabis, cannabinoids, the endocannabinoid system, and related topics especially with regard to their therapeutic potential. It supports research into cannabis products and the endocannabinoid system, and promotion of exchange of information between researchers, health care practitioners, patients, and the public.